Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC lessened its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 21.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 72,916 shares of the medical equipment provider's stock after selling 19,761 shares during the quarter. Corient Private Wealth LLC's holdings in Zimmer Biomet were worth $7,702,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Stonebridge Financial Group LLC purchased a new position in Zimmer Biomet in the fourth quarter valued at about $25,000. Dunhill Financial LLC boosted its holdings in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 218 shares in the last quarter. Brooklyn Investment Group purchased a new position in shares of Zimmer Biomet in the 3rd quarter worth approximately $35,000. Kentucky Trust Co bought a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $39,000. Finally, OFI Invest Asset Management purchased a new stake in shares of Zimmer Biomet during the 4th quarter valued at $40,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock traded down $0.74 during trading hours on Tuesday, reaching $110.50. The stock had a trading volume of 1,296,857 shares, compared to its average volume of 1,496,400. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $22.00 billion, a PE ratio of 24.83, a PEG ratio of 1.95 and a beta of 1.04. The stock's 50 day moving average is $106.86 and its 200 day moving average is $106.86.

Remove Ads

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the company earned $2.20 EPS. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet's dividend payout ratio (DPR) is currently 21.57%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.95% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ZBH. Raymond James decreased their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Barclays cut their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research note on Monday, February 10th. Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Finally, JMP Securities reissued a "market outperform" rating and issued a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Zimmer Biomet presently has an average rating of "Hold" and an average target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.